- Email: [email protected]
Project title clinical study of MRI in breast cancer
Academic Radiology,Vol 7, No 5, May 2000 fraction developed concurrently during the previous funding cycle, a more complete picture of tumor angiogenesis will be obtained. The approach will be validated in animal cancer models of new vessel growth using vascular staining and casting techniques along with quantitative autoradiography. These techniques will also be applied to humans with gliomas, validated using PET and stereotactic biopsy quantitative histology, and applied to the problem of surveillance for malignant dedifferention. In addition, these techniques will be used to study the direct physiological consequences of treatment with the promising new class of therapeutics, the anti-angiogenic agents, and their role in monitoring therapeutic effect will be evaluated in animal models and in a pilot human trial. Such studies are especially relevant in humans where little direct data on mechanism of action for these drugs exists. By providing a quantitative regional picture of the tumor microvascular bed, this research should enhance the characterization of tumors and choice of therapies in patients with brain and other systemic cancers. Thesaurus Terms: angiogenesis, blood volume, cerebrovascular visualization, neoplastic growth, nuclear magnetic resonance spectroscopy angiogenesis inhibitor, blood flow, brain mapping, contrast media, drug screening/evaluation, glioma, microcirculation, neoplasm/cancer chemotherapy, nonhuman therapy evaluation, vascular endothelium autoradiography, bioimaging/biomedical imaging, clinical research, human subject, laboratory rat, magnetic resonance imaging, positron emission tomography
Institution:
Fiscal Year: Department: Project Start: Project End: ICD: IRG:
Massachusetts General Hospital 55 Fruit St Boston, MA 02114 1999 05-Jan-89 31-Mar-02 National Cancer Institute NCI
ABSTRACTS OF NIH GRANTS characteristics of breast MRI in : detecting and diagnosing lesions in patients with suspicious mammographic or clinical findings and determining the extent of cancer within an affected breast. In addition to characterizing the performance of breast MRI as described above, factors affecting the performance such as prior knowledge of historical and mammographic features will also be evaluated. In particular, the relative importance of high resolution and dynamic imaging will be assessed. In addition, this consortium will conduct a pilot study to investigate the feasibility of screening patients that carry a breast cancer susceptibility gene with MRI. The 14 clinical sites provide experts in breast imaging, clinical MRI and MR physics to serve on the Executive and Quality Assurance committees. In addition to the clinical sites, the consortium contains mammography, and pathology Quality Assurance facilities to support this trial. The consortium has formed strategic partnerships with industry in order to acquire technical expertise in the MRI equipment used in this study and to acquire the contrast agents to be used in the study. The expertise represented in the consortium and its industry partners makes it uniquely qualified to carry out this research program. Thesaurus Terms: breast neoplasm, breast neoplasm/cancer
diagnosis, diagnosis design/evaluation, diagnosis quality / standard, magnetic resonance imaging, mammography brca gene, cooperative study, female, image enhancement, image processing, longitudinal human study, neoplasm/cancer genetics, outcomes research, women's health bioimaging/biomedical imaging, clinical research, fluorescent in situ hybridization, human subject
Institution: Fiscal Year: Department: Project Start: Project End: ICD: IRG:
University Of Pennsylvania Philadelphia, PA 19104-6380 1998 Radiology 30-Sep-97 31-Jul-01 National Cancer Institute ZCA1
~ROJECT TITLE
CLINICAL STUDY OF MRI IN BREAST CANCER Grant Number: PI Name:
5U01CA74680-02 Schnall, Mitchell D.
Abstract: DESCRIPTION: (Applicant's Description) MRI
of the breast provides higher soft tissue contrast than conventional breast imaging (mammography). This provides the potential for improved lesion detection and characterization. Studies have already demonstrated the potential for breast MR/to distinguish benign from malignant breast lesions and to detect mammographically and clinically occult cancer. In response to RFA CA-96-012, a consortium of 14 clinical sites has been organized to perform a study on the performance
'ROJECT TITL[
HIGH RESOLUTION MR IMAGING OF SUSPICIOUS BREAST LESIONS Grant Number: PI Name:
5R01CA58358-06 Schnall, Mitchell D.
Abstract: The traditional methods for breast cancer screening
(physical exam and mammography) suffer from poor specificity and a difficulty in detecting lesions in maInmographically dense breasts. Contrast enhanced magnetic resonance imaging of the breast has been suggested as a method to improve the specificity of breast imaging by differentiating benign from
379
Institution:
Fiscal Year: Department: Project Start: Project End: ICD: IRG:
Massachusetts General Hospital 55 Fruit St Boston, MA 02114 1999 05-Jan-89 31-Mar-02 National Cancer Institute NCI
ABSTRACTS OF NIH GRANTS characteristics of breast MRI in : detecting and diagnosing lesions in patients with suspicious mammographic or clinical findings and determining the extent of cancer within an affected breast. In addition to characterizing the performance of breast MRI as described above, factors affecting the performance such as prior knowledge of historical and mammographic features will also be evaluated. In particular, the relative importance of high resolution and dynamic imaging will be assessed. In addition, this consortium will conduct a pilot study to investigate the feasibility of screening patients that carry a breast cancer susceptibility gene with MRI. The 14 clinical sites provide experts in breast imaging, clinical MRI and MR physics to serve on the Executive and Quality Assurance committees. In addition to the clinical sites, the consortium contains mammography, and pathology Quality Assurance facilities to support this trial. The consortium has formed strategic partnerships with industry in order to acquire technical expertise in the MRI equipment used in this study and to acquire the contrast agents to be used in the study. The expertise represented in the consortium and its industry partners makes it uniquely qualified to carry out this research program. Thesaurus Terms: breast neoplasm, breast neoplasm/cancer
diagnosis, diagnosis design/evaluation, diagnosis quality / standard, magnetic resonance imaging, mammography brca gene, cooperative study, female, image enhancement, image processing, longitudinal human study, neoplasm/cancer genetics, outcomes research, women's health bioimaging/biomedical imaging, clinical research, fluorescent in situ hybridization, human subject
Institution: Fiscal Year: Department: Project Start: Project End: ICD: IRG:
University Of Pennsylvania Philadelphia, PA 19104-6380 1998 Radiology 30-Sep-97 31-Jul-01 National Cancer Institute ZCA1
~ROJECT TITLE
CLINICAL STUDY OF MRI IN BREAST CANCER Grant Number: PI Name:
5U01CA74680-02 Schnall, Mitchell D.
Abstract: DESCRIPTION: (Applicant's Description) MRI
of the breast provides higher soft tissue contrast than conventional breast imaging (mammography). This provides the potential for improved lesion detection and characterization. Studies have already demonstrated the potential for breast MR/to distinguish benign from malignant breast lesions and to detect mammographically and clinically occult cancer. In response to RFA CA-96-012, a consortium of 14 clinical sites has been organized to perform a study on the performance
'ROJECT TITL[
HIGH RESOLUTION MR IMAGING OF SUSPICIOUS BREAST LESIONS Grant Number: PI Name:
5R01CA58358-06 Schnall, Mitchell D.
Abstract: The traditional methods for breast cancer screening
(physical exam and mammography) suffer from poor specificity and a difficulty in detecting lesions in maInmographically dense breasts. Contrast enhanced magnetic resonance imaging of the breast has been suggested as a method to improve the specificity of breast imaging by differentiating benign from
379